PBYIPuma Biotechnology, Inc.

$311M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+11.5% YoY

Gross Profit

$45M74.9% margin

Operating Income

$12M20.3% margin

Net Income

$9M15.7% margin

EPS (Diluted)

$0.21

QoQ Revenue Growth

+30.1%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$194M

Total Liabilities

$174M

Stockholders' Equity

$20M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$53M	+11.5%
Gross Profit	$45M	$41M	+7.7%
Operating Income	$12M	-$17M	+172.5%
Net Income	$9M	-$5M	+283.5%

Revenue Segments

Product

$51M86%

Royalty

$8M14%

PBYI Q2 2022 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena